Inceptionr LLC Buys New Position in LeMaitre Vascular, Inc. $LMAT

Inceptionr LLC bought a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,061 shares of the medical instruments supplier’s stock, valued at approximately $254,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LMAT. Advisors Asset Management Inc. boosted its stake in shares of LeMaitre Vascular by 3.0% in the 2nd quarter. Advisors Asset Management Inc. now owns 4,111 shares of the medical instruments supplier’s stock valued at $341,000 after purchasing an additional 118 shares during the last quarter. Laurel Wealth Advisors LLC lifted its holdings in LeMaitre Vascular by 8,205.6% in the second quarter. Laurel Wealth Advisors LLC now owns 1,495 shares of the medical instruments supplier’s stock valued at $124,000 after buying an additional 1,477 shares during the period. XTX Topco Ltd bought a new stake in LeMaitre Vascular during the second quarter valued at $635,000. Prudential Financial Inc. grew its holdings in LeMaitre Vascular by 6.5% during the 2nd quarter. Prudential Financial Inc. now owns 21,390 shares of the medical instruments supplier’s stock worth $1,776,000 after acquiring an additional 1,300 shares during the period. Finally, Cynosure Group LLC raised its position in shares of LeMaitre Vascular by 32.8% in the 2nd quarter. Cynosure Group LLC now owns 4,926 shares of the medical instruments supplier’s stock worth $409,000 after acquiring an additional 1,217 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on LMAT shares. Weiss Ratings restated a “hold (c+)” rating on shares of LeMaitre Vascular in a research report on Wednesday. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. Barrington Research reiterated an “outperform” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a research note on Wednesday, October 15th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research note on Monday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, LeMaitre Vascular has an average rating of “Moderate Buy” and an average price target of $100.20.

LeMaitre Vascular Trading Down 0.5%

NASDAQ LMAT opened at $82.96 on Friday. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $107.22. The business has a 50 day moving average price of $87.22 and a 200-day moving average price of $87.07. The company has a market cap of $1.88 billion, a price-to-earnings ratio of 40.27, a P/E/G ratio of 2.29 and a beta of 0.77.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.05. The company had revenue of $61.05 million for the quarter, compared to analysts’ expectations of $62.18 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.LeMaitre Vascular’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period last year, the business earned $0.49 EPS. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS. As a group, equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 4th. Stockholders of record on Thursday, November 20th will be given a dividend of $0.20 per share. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $0.80 annualized dividend and a dividend yield of 1.0%. LeMaitre Vascular’s payout ratio is presently 34.48%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.